{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:43:24Z","timestamp":1791848604881,"version":"4.3.4"},"reference-count":37,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Pathogens"],"abstract":"<jats:p>Background: HPV infections with high-risk subtypes are a risk factor for developing cervical and anal cancer. Despite HPV vaccination, the incidence of cervical and anal cancer is increasing. There has been substantial research regarding the benefits of screening men who have sex with men (MSM) and those diagnosed with HIV for anal HPV and dysplasia, but little data exists for women diagnosed with cervical cancer. Methods: We constructed a Markov model in Python 3.13 to simulate the outcomes and financial impact of screening women newly diagnosed with cervical cancer for anal HPV and dysplasia. Two matrices were used to represent the screened group and the unscreened group. In the screening group, all women received initial anal HPV screening and high-resolution anoscopy with biopsy. If biopsy results confirmed HSIL, each would receive treatment with electrocautery. The screening group would also undergo annual surveillance and follow-up treatment as necessary. In the unscreened group, women did not receive screening or treatment, and the disease process was allowed to progress naturally. Results: The initial cohort consisted of 5555 women diagnosed with cervical cancer and concurrent anal HPV. The incidence of anal cancer in the screening group was 271 vs. 375 in the unscreened group after three years, 642 vs. 1236 after ten years, and 863 vs. 2039 after twenty years. Moreover, anal cancer deaths were 1236 in the screening group vs. 9041 in the unscreened group after 10 years and 31,118 vs. 51,553 after twenty years. The screened group saved 330.1 million dollars after ten years and 1.33 billion dollars after twenty years when compared to the unscreened group. Over the life of the study, the screened group would also accrue 102,000 discounted QALYs when compared to the unscreened group. Conclusions: Our model strongly suggests that screening women diagnosed with cervical cancer for anal HPV and treating anal dysplasia leads to less anal cancer, less deaths from anal cancer, less economic impact on the healthcare system, and more QALYs for patients.<\/jats:p>","DOI":"10.3390\/pathogens14101007","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T08:10:51Z","timestamp":1759738251000},"page":"1007","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patients with Newly Diagnosed Cervical Cancer Should Be Screened for Anal Human Papillomavirus (HPV) and Anal Dysplasia: Results of Cost and Quality Analysis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9535-0204","authenticated-orcid":false,"given":"Lukus","family":"Berber","sequence":"first","affiliation":[{"name":"Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Foy","sequence":"additional","affiliation":[{"name":"Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Jesus","family":"Cantu","sequence":"additional","affiliation":[{"name":"Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli D.","family":"Ehrenpreis","sequence":"additional","affiliation":[{"name":"Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"ref_1","unstructured":"Milner, D.A. (2015). Diagnostic Pathology: Infectious Diseases, Elsevier Health Sciences."},{"key":"ref_2","unstructured":"American Cancer Society (2025, July 16). Cancer Statistics Center. Available online: https:\/\/cancerstatisticscenter.cancer.org\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1158\/1055-9965.EPI-05-0460","article-title":"Anal human papillomavirus infection in women and its relationship with cervical infection","volume":"14","author":"Hernandez","year":"2005","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/ijc.34850","article-title":"The International Anal Neoplasia Society\u2019s consensus guidelines for anal cancer screening","volume":"154","author":"Stier","year":"2024","journal-title":"Int. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1001\/jama.281.19.1822","article-title":"The Clinical Effectiveness and Cost-effectiveness of Screening for Anal Squamous Intraepithelial Lesions in Homosexual and Bisexual HIV-Positive Men","volume":"281","author":"Goldie","year":"1999","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Robinson, A., Ehrenpreis, E., Dang, N., Virdi, R., and Lafazanos, Y. (2025, January 21). Analysis of temporal trends in anal cancer incidence by sex, age, and ethnicity, 2017\u20132021. Proceedings of the Scientific Day, Advocate Aurora Health, Park Ridge, IL, USA.","DOI":"10.1016\/S0016-5085(25)05232-1"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2165\/00019053-200624040-00005","article-title":"Optimal assignment of treatments to health states using a Markov decision model: An introduction to basic concepts","volume":"24","author":"Bala","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jcv.2013.11.004","article-title":"The relationship between the cervical and anal HPV infection in women with cervical intraepithelial neoplasia","volume":"59","author":"Sehnal","year":"2014","journal-title":"J. Clin. Virol."},{"key":"ref_9","unstructured":"American Cancer Society (2025, July 16). Key Statistics for Cervical Cancer. American Cancer Society. Available online: https:\/\/www.cancer.org\/cancer\/types\/cervical-cancer\/about\/key-statistics.html."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ygyno.2016.04.015","article-title":"Evaluation of anal cytology and dysplasia in women with a history of lower genital tract dysplasia and malignancy","volume":"141","author":"Cronin","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1258\/jms.2009.009058","article-title":"Perianal condylomas, anal squamous intraepithelial neoplasms and screening: A review of the literature","volume":"17","author":"Oon","year":"2010","journal-title":"J. Med. Screen."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1056\/NEJMoa2201048","article-title":"Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer","volume":"386","author":"Palefsky","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/cid\/civ628","article-title":"Long-term outcomes of adding HPV vaccine to the anal intraepithelial neoplasia treatment regimen in HIV-positive men who have sex with men","volume":"61","author":"Goldstone","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","unstructured":"National Cancer Institute (2025, July 15). SEER Cancer Stat Facts: Anus, Anal Canal and Anorectum Cancer. Surveillance, Epidemiology, and End Results Program, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/anus.html."},{"key":"ref_15","unstructured":"National Cancer Institute (2025, July 16). SEER Cancer Stat Facts: Cervix Uteri Cancer. Surveillance, Epidemiology, and End Results Program, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/cervix.html."},{"key":"ref_16","unstructured":"Social Security Administration (2025, July 16). Actuarial Life Table, 2022, as Used in the 2025 Trustees Report, Available online: https:\/\/www.ssa.gov\/oact\/STATS\/table4c6.html."},{"key":"ref_17","unstructured":"Meunning, B.P. (2016). Cost-Effectiveness Analysis in Health, John Wiley & Sons. [3rd ed.]."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1525-1497.1998.00211.x","article-title":"Interpretation of cost-effectiveness analyses","volume":"13","author":"Owens","year":"1998","journal-title":"J. Gen. Intern. Med."},{"key":"ref_19","unstructured":"Centers for Medicare, and Medicaid Services (2025, July 05). Physician Fee Schedule Overview, Available online: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search\/overview."},{"key":"ref_20","first-page":"16923","article-title":"Healthcare costs associated with anal cancer treatment: Evidence from a U.S. commercially insured population","volume":"12","author":"Deshmukh","year":"2023","journal-title":"Cancer Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pvr.2017.12.001","article-title":"Patients with newly diagnosed cervical cancer should be screened for anal human papilloma virus and anal dysplasia: Results of a pilot study using a STELLA computer simulation and economic model","volume":"5","author":"Ehrenpreis","year":"2018","journal-title":"Papillomavirus Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1086\/596758","article-title":"Duration and clearance of anal human papillomavirus (HPV) infection among women: The Hawaii HPV cohort study","volume":"48","author":"Shvetsov","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","unstructured":"US Bureau of Labor Statistics (2025, July 16). Consumer Price Index (CPI), Available online: https:\/\/www.bls.gov\/cpi\/."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Sauter, C., Peeken, J.C., Borm, K., Diehl, C., M\u00fcnch, S., Combs, S.E., and Dapper, H. (2022). Quality of life in patients treated with radiochemotherapy for primary diagnosis of anal cancer. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-08525-1"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/1055-9965.EPI-22-0793","article-title":"Cervical cancer stage at diagnosis and survival among women \u226565 years in California","volume":"32","author":"Cooley","year":"2023","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_26","unstructured":"American Association for Cancer Research (2023). Cervical cancer stage at diagnosis and survival. Cancer Epidemiol. Biomark. Prev., 32."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ijc.25080","article-title":"Immunosuppressive disorders and risk of anal squamous cell carcinoma: A nationwide cohort study in Denmark, 1978\u20132005","volume":"127","author":"Sunesen","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0016-5085(99)70549-4","article-title":"Clinical course and costs of care for Crohn\u2019s disease: Markov model analysis of a population-based cohort","volume":"117","author":"Silverstein","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_29","unstructured":"National Center for Biotechnology Information (2025, July 16). Anal Cancer, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK543650\/."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/QCO.0000000000000337","article-title":"Human papillomavirus as a cause of anal cancer and the role of screening","volume":"30","author":"Gosens","year":"2017","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4149\/neo_2015_037","article-title":"Impact of risk factors on prevalence of anal HPV infection in women with simultaneous cervical lesion","volume":"62","author":"Slama","year":"2015","journal-title":"Neoplasma"},{"key":"ref_32","unstructured":"UK National Screening Committee (2022, September 29). Criteria for Appraising the Viability Effectiveness Appropriateness of a Screening Programme, GOV. UK, Available online: https:\/\/www.gov.uk\/government\/publications\/evidence-review-criteria-national-screening-programmes\/criteria-for-appraising-the-viability-effectiveness-and-appropriateness-of-a-screening-programme."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1463-1318.2010.02493.x","article-title":"Anal Cancer: Position Statement of the Association of Coloproctology of Great Britain and Ireland","volume":"13","author":"Scholefield","year":"2011","journal-title":"Color. Dis."},{"key":"ref_34","first-page":"e000013","article-title":"Chinese expert consensus on diagnosis and treatment of anal cancer","volume":"4","author":"Li","year":"2024","journal-title":"Glob. Community Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/QAI.0b013e3182437469","article-title":"Electrocautery ablation of high-grade anal squamous intraepithelial lesions in HIV-negative and HIV-positive men who have sex with men","volume":"59","author":"Marks","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10350-008-9233-4","article-title":"High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: A ten-year experience","volume":"51","author":"Pineda","year":"2008","journal-title":"Dis. Colon Rectum"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1586\/14787210.2016.1174065","article-title":"Anal human papillomavirus infection: Prevalence, diagnosis and treatment of related lesions","volume":"14","author":"Benevolo","year":"2016","journal-title":"Expert Rev. Anti-Infect. Ther."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/10\/1007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T08:27:10Z","timestamp":1759739230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/10\/1007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["pathogens14101007"],"URL":"https:\/\/doi.org\/10.3390\/pathogens14101007","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]}}}